
EU’s CHMP supports 14 new medicines, but rejects lecanemab
The European Medicine Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) recommended 14 medicines for approval at its July 2024 meeting. However, the CHMP recommended not granting a marketing authorisation for Leqembi (lecanemab) for the treatment of Alzheimer’s disease. The committee said that the observed effect of Leqembi… Read More












